You are here: Industry Insights > Sanofi

News List

Emergent BioSolutions to buy Sanofi’s smallpox vaccine business for $125m pharmaceutical-technology
July 18, 2017
US-based Emergent BioSolutions has entered an agreement to buy the ACAM2000, smallpox vaccine business of French pharmaceutical company Sanofi for up to $125m.
Amid dustup over taxpayer-funded research, Sanofi executive says it never rejected a Zika vaccine fa fiercepharma
July 17, 2017
After taking a beating in countless press reports over its Zika vaccine partnership with the U.S. Army, Sanofi is hoping to clear the air. In a series of letters to a U.S. Army official and U.S. senators, executives said Sanofi never rejected a fair prici
Sanofi gets a flu vaccines booster with $650M-plus Protein Sciences buy fiercepharma
July 14, 2017
Twice over the last year, Sanofi has come up short in high-stakes attempts at top M&A prospects. Now, the drugmaker has finally bagged an acquisition, though not on the scale of its runs for Medivation or Actelion.
Sanofi to acquire Protein Sciences cphi-online
July 13, 2017
Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur's portfolio.
Sanofi agrees to buy Protein Sciences for $750m pharmaceutical-technology
July 13, 2017
Sanofi has entered an agreement to acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut, US.
Sanofi $750m acquisition gives it edge in flu vacccine market pharmaphorum
July 12, 2017
Sanofi is to buy the vaccines biotech Protein Sciences in a deal worth up to $750 million, after missing out on bigger acquisitions.
Sanofi and Regeneron announce approval of Kevzara to treat rheumatoid arthritis in the European Unio biospectrumasia
June 30, 2017
Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R) and blocks pro-inflammatory IL-6 mediated signaling
Sanofi and Regeneron announce EC approval of Kevzara (sarilumab) expressbpd
June 28, 2017
It is used to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union
Sanofi, Gilead eyeing the takeover of Tesaro biospectrumasia
June 14, 2017
The company that acquires Tesaro will get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer
Sanofi and Boehringer Ingelheim confirm closing of business swap date europeanpharmaceuticalreview
June 07, 2017
Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page